OPKO Health (NASDAQ:OPK) Sees Strong Trading Volume – Should You Buy?

OPKO Health, Inc. (NASDAQ:OPK) shares saw unusually-strong trading volume on Monday . Approximately 7,412,277 shares changed hands during trading, an increase of 179% from the previous session’s volume of 2,659,488 shares.The stock last traded at $1.52 and had previously closed at $1.52.

Analyst Upgrades and Downgrades

Several research firms have weighed in on OPK. Barrington Research reaffirmed an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a research report on Friday, November 8th. HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of OPKO Health in a research note on Wednesday, January 8th. Finally, StockNews.com cut shares of OPKO Health from a “hold” rating to a “sell” rating in a research report on Wednesday, January 15th.

OPKO Health Price Performance

The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The stock’s fifty day moving average price is $1.52 and its 200-day moving average price is $1.52. The firm has a market cap of $1.02 billion, a PE ratio of -7.89 and a beta of 1.63.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.13. The business had revenue of $173.60 million during the quarter, compared to the consensus estimate of $181.32 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. During the same quarter in the previous year, the company posted ($0.11) EPS. As a group, equities analysts forecast that OPKO Health, Inc. will post -0.25 EPS for the current fiscal year.

Insider Buying and Selling

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 500,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The stock was purchased at an average cost of $1.56 per share, for a total transaction of $780,000.00. Following the completion of the purchase, the chief executive officer now owns 212,411,477 shares of the company’s stock, valued at $331,361,904.12. This trade represents a 0.24 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders purchased 2,001,792 shares of company stock worth $3,054,984. 47.26% of the stock is owned by corporate insiders.

Institutional Trading of OPKO Health

A number of institutional investors and hedge funds have recently made changes to their positions in OPK. FMR LLC lifted its position in OPKO Health by 103.6% during the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 11,089 shares in the last quarter. Algert Global LLC acquired a new position in shares of OPKO Health during the 2nd quarter valued at $44,000. Orion Portfolio Solutions LLC purchased a new stake in OPKO Health during the 3rd quarter worth $45,000. Ieq Capital LLC acquired a new stake in OPKO Health in the 4th quarter valued at $52,000. Finally, Private Advisor Group LLC raised its position in OPKO Health by 242.7% in the third quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 25,000 shares during the period. 64.63% of the stock is currently owned by institutional investors and hedge funds.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.